|
|
|
|
|
|
|
M T W Th Fri |
|
11 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
A new report from a trade group says there are only biosimilars in the works for 20% of drugs to come off patent by 2030 and none for later expiries, risking an estimated $189 billion in savings. I have the news here. |
|
|
|
Max Bayer |
Senior Reporter, Endpoints News
|
|
|
|
|
|
|
by Max Bayer
|
A trade group representing generics and biosimilars is warning that the lack of product development could imperil billions of dollars in potential savings. The new... | |
|
|
|
|
|
|
|
|
by Kyle LaHucik
|
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is plotting a major fundraise... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Sino Biopharm and AtomVie. Yarrow gets more money: New Haven-based Yarrow Bioscience priceda $150 million offering at $26 per share YARW... | |
|
|
|
|
|
|
|
